N@N

Andreas Argyrides Reiterated (SRPT) at Buy and Held Target at $224 on, Feb 20th, 2024

Andreas Argyrides of Wedbush, Reiterated "Sarepta Therapeutics, Inc." (SRPT) at Buy and Held Target at $224 on, Feb 20th, 2024.

Andreas has made no other calls on SRPT in the last 4 months.

There are 10 other peers that have a rating on SRPT. Out of the 10 peers that are also analyzing SRPT, 1 agrees with Andreas's Rating of Hold. Following is the relevant analyst calls for the last 4 months

---

• Kristen Kluska of "Cantor Fitzgerald" Reiterated at Hold and Held Target at $128 on, Thursday, February 15th, 2024

These are the ratings of the 9 analyists that currently disagree with Andreas

---

• Gil Blum of "Needham" Maintained at Strong Buy with Increased Target to $169 on, Friday, February 16th, 2024
• Uy Ear of "Mizuho" Maintained at Strong Buy with Increased Target to $145 on, Wednesday, February 14th, 2024
• Kostas Biliouris of "BMO Capital" Initiated at Buy and Held Target at $170 on, Wednesday, January 31st, 2024
• Brian Abrahams of "RBC Capital" Maintained at Buy with Decreased Target to $151 on, Thursday, January 25th, 2024
• David Hoang of "Citigroup" Initiated at Strong Buy and Held Target at $113 on, Wednesday, December 13th, 2023
• Neena Bitritto-Garg of "Deutsche Bank" Initiated at Strong Buy and Held Target at $109 on, Tuesday, December 12th, 2023
• Gena Wang of "Barclays" Maintained at Buy with Decreased Target to $141 on, Thursday, November 2nd, 2023
• Anupam Rama of "JP Morgan" Maintained at Buy with Decreased Target to $115 on, Tuesday, October 31st, 2023
• Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $146 on, Tuesday, October 31st, 2023

Contributing Sources

---